Completed PHASE3 INTERVENTIONAL NCT00076544

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain

Sponsor: Elan Pharmaceuticals

Conditions Pain

Interventions Ziconotide

Updated 6 times since 2017 Last updated: Dec 10, 2015 Started: Feb 29, 2004 Primary completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00076544, this PHASE3 trial focuses on Pain and remains completed. Sponsored by Elan Pharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elan Pharmaceuticals

Data source: Elan Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Allentown, United States , Arvada, United States , Atlanta, United States , Bay Shore, United States , Bethpage, United States , Beverly Hills, United States , Buffalo, United States , Charleston, United States , Charlottesville, United States and 51 more locations